Treatment‐associated toxicities reported by patients with early‐stage invasive breast cancer

Friese, Christopher R.; Harrison, Jordan; Janz, Nancy K.; Jagsi, Reshma; Morrow, Monica; Li, Yun; Hamilton, Ann S.; Ward, Kevin C.; Kurian, Allison W.; Katz, Steven J.; Hofer, Timothy P.

doi:10.1002/cncr.30547

Cited by 73 publications

(53 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The findings should be reassuring to women undergoing mastectomy with or without breast reconstruction. In contrast to the toxicities associated with medical treatments for breast cancer, which are reported as severe by 45% of patients and are associated with substantial impairment of quality of life, surgical complications are less frequent and are associated with much less harm . The one area of concern is related to flap‐related complications in women undergoing immediate reconstruction.…”

Section: Discussionmentioning

confidence: 99%

The association between complications and quality of life after mastectomy and breast reconstruction for breast cancer

Browne

Jeevan

Gulliver-Clarke

et al. 2017

Cancer

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

The association between complications and quality of life after mastectomy and breast reconstruction for breast cancer

Browne

Jeevan

Gulliver-Clarke

et al. 2017

Cancer

View full text Add to dashboard Cite

show abstract

“…Sample size (N) was calculated based on single proportion formula [N � Z 2 * P (1 − P)/d 2 ] with 0.05 margins of errors (d), 95% confidence interval (Z � 1.96). And the prevalence (P) of at least one chemotherapy ADR in breast cancer patients was 93% [17]. Hence, 101 patients are at least required.…”

Section: Exclusion Criteriamentioning

confidence: 99%

Patterns of Anthracycline-Based Chemotherapy-Induced Adverse Drug Reactions and Their Impact on Relative Dose Intensity among Women with Breast Cancer in Ethiopia: A Prospective Observational Study

Alemayehu

Assefa

Tefera

et al. 2020

Journal of Oncology

View full text Add to dashboard Cite

Background. e breast cancer chemotherapy leads to diverse aspects of noxious or unintended adverse drug reactions (ADRs) that cause the relative dose intensity (RDI) reduced to below optimal (i.e., if the percentage of actual dose received per unit time divided by planned dose per unit time is less than 85%). Hence, this prospective observational study was conducted to evaluate chemotherapy-induced ADRs and their impact on relative dose intensity among women with breast cancer in Ethiopia.Methods. e study was conducted with a cohort of 146 patients from January 1 to September 30, 2017, Gregorian Calendar (GC) at the only nationwide oncology center, Tikur Anbessa Specialized Hospital (TASH), Addis Ababa, Ethiopia. e ADRs of the chemotherapy were collected using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) (version 4.03). e patients were personally interviewed for subjective toxicities, and laboratory results and supportive measures were recorded at each cycle. SPSS version 22 was used for analysis. Results. Grade 3 neutropenia (23 (15.8%)) was the most frequently reported ADR among grade 3 hematological toxicity on cycle 4. However, overall grade fatigue (136 (93.2%)) and grade 3 nausea (31 (21.2%)) were the most frequently reported nonhematological toxicities on cycle 1. e majority of ADRs were reported during the first four cycles except for peripheral neuropathy. Oral antibiotics and G-CSF use (17 (11.6%)) and treatment delay (31 (21.2%)) were frequently reported on cycle 3. Overall, 61 (41.8%) and 42 (28.8%) of study participants experienced dose delay and used G-CSF, respectively, at least once during their enrollment. Of the 933 interventions observed, 95 (10%) cycles were delayed due to toxicities in which neutropenia attributed to the delay of 89 cycles. Forty-four (30.1%) of the patients received overall RDI < 85%. Pretreatment hematological counts were significant predictors (P < 0.05) for the incidence of first cycle hematological toxicities such as neutropenia, anemia, and leukopenia and nonhematological toxicities like vomiting. Conclusion. Ethiopian women with breast cancer on anthracycline-based AC and AC-T chemotherapy predominantly experienced grade 1 to 3 hematological and nonhematological ADRs, particularly during the first four cycles. Neutropenia was the only toxicity that led to RDI < 85%. us, enhancing the utilization of G-CSF and other supportive measures will improve RDI to above 85%.

show abstract

“…Severe toxicity was reported in 866 (45%) cases and was associated with Latina versus white ethnicity (OR: 1.3; 95% CI: 1.1-1.5) [88].…”

Section: Differences In Response and Tolerance To Treatment Chemotherapymentioning

confidence: 99%

Genetics, Tumor Features and Treatment Response of Breast Cancer in Latinas

Castañeda

Castillo

Villarreal‐Garza

et al. 2018

Breast Cancer Manag.

View full text Add to dashboard Cite

Practice pointsr Latinas with breast cancer have been associated with lower prevalence and higher mortality rates. r The access to healthcare system for Latinas has been described as lower than for white women. r Rates of grade III and triple-negative phenotype breast cancer are higher for Latinas than for white women. r BRCA mutation prevalence appears to be higher in Latinas than white women in the American population. r Distribution of BRCA mutation differs by country in Central, Latin America or Caribbean and recurrent mutations have been described in Mexico. r Finally, evaluated information about treatment efficacy and toxicity in Latinas with breast cancer indicate similar effects than in the white race.Breast cancer is a heterogeneous and genetic disease that has variability according to ethnicity and race with respect to incidence, clinical characteristics and prognosis. The incidence of breast cancer is lower but mortality is higher in Latinas than Caucasians in the US series. Risk factors appear to have different prevalence and impact in Latinas. Breast cancer in Latinas has particular clinic-pathological features including younger age, higher rates of triple-negative subtype and advanced stages. Molecular studies find that Latinas from every region have a specific BRCA incidence and a recurrent mutation, as well as differences in activity of molecular pathways. Treatment response rates and toxicity have also been compared, and no difference was found between Latinas and other ethnic groups.

show abstract

Treatment‐associated toxicities reported by patients with early‐stage invasive breast cancer

Cited by 73 publications

References 27 publications

The association between complications and quality of life after mastectomy and breast reconstruction for breast cancer

The association between complications and quality of life after mastectomy and breast reconstruction for breast cancer

Patterns of Anthracycline-Based Chemotherapy-Induced Adverse Drug Reactions and Their Impact on Relative Dose Intensity among Women with Breast Cancer in Ethiopia: A Prospective Observational Study

Genetics, Tumor Features and Treatment Response of Breast Cancer in Latinas

Contact Info

Product

Resources

About